Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Beat The Bear With 3 Tools: Dividends, Dividends And Dividends

Published 07/10/2022, 08:28 AM

It’s not easy to be upbeat in a bear market. This goes for people—and especially dividend stocks.

(And hey, who has time for feelings? We are looking to get paid without losing our entire portfolios. We’ll share emotions when the bear is done.

For contrarians like you and me, it’s a time to be optimistic. We should be thinking about bargains, bargains and even more bargains.

Now halfway through the year, every major index is deep in the red. The S&P 500, NASDAQ Composite, and even the small-cap Russell 2000 are all in bear-market territory, while the Dow Jones Industrial Average is down considerably too.

Nowhere to Hide in ‘22
Markets Down 2022

It’s no secret why.

Inflation has gone bonkers (a technical term). According to the Bureau of Labor Statistics, May’s annual inflation rate was a ludicrous 8.6%—the highest level seen since 1981! The Federal Reserve has slammed the monetary brakes in response, raising rates and green-lighting quantitative tightening to cool off consumer prices—at the very real risk of sparking a depression.

All the while, a warmongering Russia has only made things worse. Most of the developed world has weened itself off Russian oil, juicing commodity prices, plus its actions have further frayed a global supply chain already tattered by COVID.

So while no one is happy that stocks are getting pummeled, by this point, they’re probably not surprised, either.

But there has been one pleasant surprise in 2022:

Dividend Stocks Hang Tough
Dividends Weather The Storm

Higher-yielding dividend stocks haven’t been entirely immune from the market’s downturn, but they have certainly provided better protection than our average vanilla blue chip.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

There’s no one single reason. Some of this is investors piling into traditional safety sectors (think utilities and consumer staples). Some of this is a fantastic year-to-date performance from energy stocks thanks to sky-high oil prices. And some of this is a rush into anything with a decent yield as Wall Street bets on further rate hikes later this year.

Indeed, while the market looks for its eventual bottom, a handful of dividend payers have recently scratched out 52-week highs!

Thing is, if many of these headwinds refuse to subside, these unlikely momentum stocks might have still more gas left in the tank.

A few noteworthy stocks worth your attention right now:

Donegal Group (NASDAQ:DGICA, 4.1% Yield): Donegal Group has been nothing short of stellar in 2022—though chances are you haven’t heard anything about it. While Donegal has been around for more than 125 years in one form or another, it remains a smallish mid-cap insurer providing full lines of personal, farm and commercial insurance products across various parts of the U.S. Commercial lines have grown in nine of the past 10 years, and retention rates have recently climbed above 90%. During its most recent quarter, net premiums improved by 6.4% and net investment income was up by 4.6%. Those results have helped DGICA run 23% higher in 2022 while its insurance brethren are off 4% and the broader financial sector is down by double digits. Also noteworthy is persistent, if modest, dividend growth—the payout is up 18% since 2018.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Donegal Gives an Irish Goodbye to Its Peers
DGICA-Total Returns

Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK) (TAK, 5.8% Yield): When you think of Big Pharma and its above-average yields, you probably think of American mainstays like Pfizer (NYSE:PFE) and Eli Lilly (NYSE:LLY), or even European plays like AstraZeneca (NASDAQ:AZN) and Novartis AG ADR (NYSE:NVS) (Novartis AG (SIX:NOVN)). But from a dividend standpoint, Tokyo-based Takeda Pharmaceutical Co., Ltd. (TYO:4502) takes the tako. Takeda boasts drugs including Entyvio (ulcerative colitis, Crohn’s disease), Vyvanse (ADHD) and Advate (hemophilia). In May, Takeda delivered a solid fiscal 2021 report, but more impressive was its forecast for 2022, which included estimates for nearly 28% bottom-line growth—numbers it expects won’t be materially affected by COVID nor the Russian war with Ukraine. Just remember: Takeda is an international company, and it pays dividends accordingly. Like many of its European counterparts, however, TAK only pays semiannually, and the payout has remained level for more than a decade.

British American Tobacco (NYSE:BTI, 6.8% Yield): British American Tobacco looks as bulletproof as it ever has. Remember: BTI bought competitor Reynolds American in 2017 to improve scale, and it has entered new product types, including vaping. It is navigating a few challenges over the past couple years, such as selling its business in Iran and trying to transfer its Russian business. But the company expects revenues to grow 2% to 4% this year, and adjusted EPS to rise by mid-single digits—despite the entire globe cracking down on tobacco use. Moreover, the company says it should return about $2.5 billion via share buybacks this year. Better still: BTI switched from semiannual to quarterly dividends in 2018 and has been slowly but surely turning up the heat for years.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Disclosure: Brett Owens and Michael Foster are contrarian income investors who look for undervalued stocks/funds across the U.S. markets. Click here to learn how to profit from their strategies in the latest report, "7 Great Dividend Growth Stocks for a Secure Retirement."

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.